Back to discover

Protein / target

Elastin

Encoded byELNP15502Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
1
Clinical candidates
Antibody-tractable
Druggability
UniProt loc high conf
1
Research papers

Protein at a glance

Biological role

Extracellular matrix constituent conferring elasticity

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene ELN · Genetic evidence · score 0.80

Therapeutic position

Clinically advancing target

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely.

View complete UniProt function annotation

Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely. Molecular determinant of the late arterial morphogenesis, stabilizing arterial structure by regulating proliferation and organization of vascular smooth muscle (By similarity)

Subcellular location

Secreted, extracellular space, extracellular matrix
Domains and Gene Ontology detail (13)

Gene Ontology

  • Celastic fiber
  • Cextracellular matrix
  • Cextracellular region
  • Fextracellular matrix binding
  • Fextracellular matrix constituent conferring elasticity
  • Fextracellular matrix structural constituent
  • Panimal organ morphogenesis
  • Paortic valve morphogenesis
  • Pblood circulation
  • Pextracellular matrix assembly
  • Poutflow tract morphogenesis
  • Pregulation of smooth muscle cell proliferation

786 aa · 68 kDa · 13 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell adhesionUniProt · GO
View supporting evidence

Cell adhesion

  • ·Secreted, extracellular space, extracellular matrix
  • ·extracellular matrix
  • ·extracellular matrix binding
  • ·extracellular matrix constituent conferring elasticity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ELN

Gene-level evidence surfaced through the gene ELN that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn
0.80Well supported

Genetic evidence dominant · Open Targets 0.49

Neurodegenerative Diseases
0.32Preliminary

Pathway evidence dominant · Open Targets 0.48 · no direct causal or clinical evidence

View evidence synthesis (2)
Genetic Diseases, InbornWell supported
0.80
agreement 0.660.94
Genetic98%Literature2%

Open Targets aggregate 0.49 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.32
agreement 0.140.50
Pathway96%Literature4%

Open Targets aggregate 0.48 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Genetic Diseases, Inborn0.49
Neurodegenerative Diseases0.48

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
VONAPANITASEPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (5)
AB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.